11 results on '"Harel, Stéphanie"'
Search Results
2. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
- Author
-
Bigenwald, Camille, Harel, Stéphanie, Chevignon, Florian, Roos‐Weil, Damien, Bernard, Olivier A., Amorim, Sandy, Brice, Pauline, Adès, Lionel, Nloga, Anne Marie, Sébert, Marie, Braun, Thorsten, Eclache, Virginie, Thieblemont, Catherine, and Fenaux, Pierre
- Subjects
- *
MYELODYSPLASTIC syndromes , *MYELODYSPLASTIC syndromes treatment , *LEUKEMIA treatment , *LYMPHOMA treatment , *CHEMOTHERAPY complications , *RADIOTHERAPY complications - Abstract
The article discusses a study which examined the clinical and biological characteristics of patients with both myelodysplastic syndromes/acute myeloid leukaemia (MDS/AML) and lymphoma. Topics include the complications of cytotoxic chemotherapy (CT) and radiotherapy (RT), the occurrence of MDS/AML in patients with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL), and the diagnosis of MDS/AML.
- Published
- 2018
- Full Text
- View/download PDF
3. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
- Author
-
Harel, Stéphanie, Cherait, Amina, Berthon, Céline, Willekens, Christophe, Park, Sophie, Rigal, Marthe, Brechignac, Sabine, Thépot, Sylvain, Quesnel, Bruno, Gardin, Claude, Adès, Lionel, Fenaux, Pierre, and Braun, Thorsten
- Subjects
- *
MYELODYSPLASTIC syndromes , *HEALTH outcome assessment , *DECITABINE , *AZACITIDINE , *HEMATOPOIETIC stem cell transplantation , *PATIENTS , *DISEASE risk factors , *THERAPEUTICS - Abstract
Outcome of patients with high risk MDS and CMML who failed treatment with azacitidine remains poor with a median survival of 6 months, without established therapy available except allogeneic hematopoietic stem cell transplantation. The objective of our study was to evaluate efficacy of decitabine after azacitidine failure in a relatively large patient cohort based on conflicting results with 0–28% response rates (RR) in this setting in small patient series. Thirty-six consecutive high risk MDS and CMML patients who received decitabine after azacitidine failure were retrospectively reviewed. Response was based on IWG 2006 criteria for MDS and CMML with WBC <13 G/l and also included for proliferative CMML the evolution of WBC, splenomegaly (SMG) and extramedullary disease (EMD). Patients received a median number of 3 (range 1–27) cycles of decitabine and 12 patients received at least 6 cycles. Seven (19.4%) patients were responders including 3 marrow CR (mCR), 2 stable disease (SD) with HI-E, 1 SD with HI-N and HI-P and 1 SD with HI-N. In a CMML patient with SD, specific skin lesions resolved with decitabine. Responses were generally short lived (2–5 months) except 1 responder currently ongoing with +11 months follow up. Two non-responders had prolonged SD (without HI) of 21 and 27 months duration respectively. Median OS from onset of decitabine was 7.3 months, without significant difference between responders and non-responders. Treatment with decitabine after azacitidine failure yielded modest ORR (19.4%) with short response duration and poor OS. Thus, use of decitabine in such patients who failed or progressed after azacitidine cannot be recommended, underscoring the need for novel strategies in this setting. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.
- Author
-
Jourdes, Aurélie, Cellerin, Elise, Touzeau, Cyrille, Harel, Stéphanie, Denis, Blandine, Escure, Guillaume, Faure, Emmanuel, Jamard, Simon, Danion, Francois, Sonntag, Cécile, Ader, Florence, Karlin, Lionel, Soueges, Sarah, Cazelles, Clarisse, de La Porte des Vaux, Clémentine, Frenzel, Laurent, Lanternier, Fanny, Brousse, Xavier, Cazaubiel, Titouan, and Berger, Pierre
- Subjects
- *
BISPECIFIC antibodies , *MULTIPLE myeloma , *CYTOKINE release syndrome , *RESPIRATORY infections , *INFECTION - Abstract
Bispecific antibodies (BsAbs) are an effective treatment used in relapsed or refractory multiple myeloma. Despite a well-tolerated safety profile, infectious events appear to be frequent in clinical trials. Real-world data on epidemiology, characteristics, risk factors, and outcomes of infections in patients treated with BsAb are still needed. A retrospective, multicentre study in BsAb-treated patients with multiple myeloma was performed in 14 French centres from December 2020 to February 2023. The primary objective was to describe the incidence of infections that required hospitalization, specific treatment, or adaptation in BsAb administration. Among 229 patients with multiple myeloma treated with BsAb, 153 (67%) received teclistamab, 47 (20%) received elranatamab, and 29 (13%) talquetamab. We reported a total of 234 infections, including 123 (53%) of grade of ≥3. Predominant infections affected the respiratory tract (n = 116, 50%) followed by bacteraemias (n = 36, 15%). The hospitalization rate was 56% (n = 131), and 20 (9%) infections resulted in death. Global cumulative incidence of the first infection was 70% in all patients, 73% in patients treated with B-cell maturation antigen-targeting, and 51% with GPRC5D-targeting BsAb. In univariate analyses, corticosteroids for cytokine release syndrome (CRS)/immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with a higher risk of first infection (HR = 2.13; 95% CI, 1.38–3.28), whereas GPRC5D-targeting BsAb and anti-bacterial prophylaxis were associated with a lower risk (HR = 0.53; 95% CI, 0.3–0.94 and HR = 0.65; 95% CI, 0.46–0.9). Fine and Gray multivariate model found that only corticosteroids for CRS/ICANS were correlated with a higher risk of first infection (HR = 2.01; 95% CI, 1.27–3.19). The implementation of preventive measures that aim to mitigate the risk of infection under BsAb is pivotal, notably in patients who received corticosteroids for CRS/ICANS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Thiotepa intrathecal injections for myelomatous central nervous system involvement.
- Author
-
Claudel, Alexis, Talbot, Alexis, Harel, Stéphanie, Royer, Bruno, Naelle, Lombion, Zagdanski, Anne‐Marie, Madelaine, Isabelle, Lemaire, Pierre, and Arnulf, Bertrand
- Subjects
- *
CENTRAL nervous system , *INTRATHECAL injections , *MENINGEAL cancer - Abstract
After relapse or progression of the CNS-MM disease, four of the 13 (31%) patients continued to receive second-line therapy for CNS-MM and one of 13 (8%) a third-line therapy. Keywords: multiple myeloma; central nervous system; extramedullary disease; intrathecal injections; thiotepa EN multiple myeloma central nervous system extramedullary disease intrathecal injections thiotepa e9 e12 4 04/19/21 20210415 NES 210415 The worldwide incidence of multiple myeloma (MM) has been rising continuously, representing an overall increase of 126% from 1990 to 2016 in almost all regions, regardless of socio-demographic status and availability of sensitive diagnostic techniques.1 Though remarkable progress has been made, the disease is still currently incurable. Emergence of central nervous system myeloma in the era of novel agents: CNS myeloma. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
6. The use of ICU resources in CAR-T cell recipients: a hospital-wide study.
- Author
-
Valade, Sandrine, Darmon, Michael, Zafrani, Lara, Mariotte, Eric, Lemiale, Virginie, Bredin, Swann, Dumas, Guillaume, Boissel, Nicolas, Rabian, Florence, Baruchel, André, Madelaine, Isabelle, Larghero, Jérôme, Brignier, Anne, Lengliné, Etienne, Harel, Stéphanie, Arnulf, Bertrand, Di Blasi, Roberta, Thieblemont, Catherine, and Azoulay, Elie
- Subjects
- *
CYTOKINE release syndrome , *B cell lymphoma , *CHIMERIC antigen receptors , *CATHETER-related infections , *MULTIPLE myeloma , *DIFFUSE large B-cell lymphomas - Abstract
Background: CAR-T cell (chimeric antigen receptor T) therapy has emerged as an effective treatment of refractory hematological malignancies. Intensive care management is intrinsic to CAR-T cell therapy. We aim to describe and to assess outcomes in critically ill CAR-T cell recipients. Study design and methods: Hospital-wide retrospective study. Consecutive CAR-T cell recipients requiring ICU admission from July 2017 and December 2020 were included. Results: 71 patients (median age 60 years [37–68]) were admitted to the ICU 6 days [4–7] after CAR-T cell infusion. Underlying malignancies included diffuse large B cell lymphoma (n = 53, 75%), acute lymphoblastic leukemia (17 patients, 24%) and multiple myeloma (n = 1, 1.45%). Performance status (PS) was 1 [1–2]. Shock was the main reason for ICU admission (n = 40, 48%). Isolated cytokine release syndrome (CRS) was the most common complication (n = 33, 46%), while 21 patients (30%) had microbiologically documented bacterial infection (chiefly catheter-related infection). Immune effector cell-associated neurotoxicity syndrome was reported in 26 (37%) patients. At ICU admission, vasopressors were required in 18 patients (25%) and invasive mechanical ventilation in two. Overall, 49 (69%) and 40 patients (56%) received tocilizumab or steroids, respectively. Determinant of mortality were the reason for ICU admission (disease progression vs. sepsis or CRS (HR 4.02 [95%CI 1.10–14.65]), Performance status (HR 1.97/point [95%CI 1.14–3.41]) and SOFA score (HR 1.16/point [95%CI 1.01–1.33]). Conclusions: Meaningful survival could be achieved in up to half the CAR-T cell recipients. The severity of organ dysfunction is a major determinant of death, especially in patients with altered performance status or disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Profiles and outcomes in patients with COVID-19 admitted to wards of a French oncohematological hospital: A clustering approach.
- Author
-
Bondeelle, Louise, Chevret, Sylvie, Cassonnet, Stéphane, Harel, Stéphanie, Denis, Blandine, de Castro, Nathalie, and Bergeron, Anne
- Subjects
- *
COVID-19 , *SURVIVAL rate , *PROGNOSIS , *OLDER patients , *PHYSICIANS - Abstract
Objectives: Although some prognostic factors for COVID-19 were consistently identified across the studies, differences were found for other factors that could be due to the characteristics of the study populations and the variables incorporated into the statistical model. We aimed to a priori identify specific patient profiles and then assess their association with the outcomes in COVID-19 patients with respiratory symptoms admitted specifically to hospital wards. Methods: We conducted a retrospective single-center study from February 2020 to April 2020. A non-supervised cluster analysis was first used to detect patient profiles based on characteristics at admission of 220 consecutive patients admitted to our institution. Then, we assessed the prognostic value using Cox regression analyses to predict survival. Results: Three clusters were identified, with 47 patients in cluster 1, 87 in cluster 2, and 86 in cluster 3; the presentation of the patients differed among the clusters. Cluster 1 mostly included sexagenarian patients with active malignancies who were admitted early after the onset of COVID-19. Cluster 2 included the oldest patients, who were generally overweight and had hypertension and renal insufficiency, while cluster 3 included the youngest patients, who had gastrointestinal symptoms and delayed admission. Sixty-day survival rates were 74.3%, 50.6% and 96.5% in clusters 1, 2, and 3, respectively. This was confirmed by the multivariable Cox analyses that showed the prognostic value of these patterns. Conclusion: The cluster approach seems appropriate and pragmatic for the early identification of patient profiles that could help physicians segregate patients according to their prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature.
- Author
-
Elessa, Dikélélé, Talbot, Alexis, Lombion, Naëlle, Harel, Stéphanie, Galicier, Lionel, Veyradier, Agnès, Joly, Bérangère, Andreoli, Annalisa, Rigaudeau, Sophie, Azoulay, Élie, Coppo, Paul, Royer, Bruno, and Arnulf, Bertrand
- Subjects
- *
THROMBOTIC thrombocytopenic purpura , *ACTIVATED protein C resistance , *LITERATURE reviews , *IDIOPATHIC thrombocytopenic purpura , *PATHOLOGY - Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy (TMA) syndrome (Kremer et al. [8]). These three cases of TTP occurred during lenalidomide therapy (Table)- there was nothing that can usually be associated with thrombotic microangiopathy - no infectious trigger, no association with other autoimmune disorders, and no drugs intake. For our patients, the presence of anti-ADAMTS13 antibodies in each case and the efficacy of TPE and/or rituximab therapies imply an immune-mediated reaction. Montefusco et al. ([10]) described six autoimmune diseases after lenalidomide administration to 140 patients (4-3%): three autoimmune cytopenias and three organ-specific autoimmune disorders, occurring mostly in the first months of treatment. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
9. Un cas de myélome phagocytaire et revue de la littérature.
- Author
-
Brumpt, Caren, Baron, Marine, Vignon, Marguerite, Meignin, Véronique, Noguera, Maria-Elena, Harel, Stéphanie, and Arnulf, Bertrand
- Abstract
Phagocytosis of blood cells by malignant plasma cells in multiple myelome is an extremely rare condition. We report the case of a 75 years-old woman presented with pancytopenia. Bone marrow aspiration revealed an infiltrate of atypical plasma cells and 20% of them contained phagocytosed red blood cells, erythroid progenitors. Laboratory values for calcium, blood urea, creatinin, lactate deshydrogenase were normal. Osteolytic lesions were absent. On the basis of the few reported cases, hemophagocytosis does not appear to be associated with a particular clinical presentation, nor with any biological characteristics. The hemophagocytosis mechanism in myeloma is unknown. In vitro studies have demonstrated the phagocytic potential of myeloma cells. Aberrant CD15 expression might be related to phagocytic function of plasma cells. It has been shown that myeloma cells act as antigen-presenting immature cells with hemophagocytosis activity. This case report highlights the relevance of investigating hemophagocytosis activity by plasmocytes in case of pancytopenia. Further studies are needed to explain the pathophysiology. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment.
- Author
-
Amorim, Sandy, Fleury, Isabelle, Mounier, Nicolas, Harel, Stéphanie, Brice, Pauline, and Thieblemont, Catherine
- Subjects
- *
MITOXANTRONE , *RITUXIMAB , *STEM cell transplantation - Abstract
A letter to the editor is presented in response to the article "Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment" in the previous issue.
- Published
- 2016
- Full Text
- View/download PDF
11. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy.
- Author
-
Szalat, Raphael, Arnulf, Bertrand, Karlin, Lionel, Rybojad, Michel, Asli, Bouchra, Malphettes, Marion, Galicier, Lionel, Vignon-Pennamen, Marie-Dominique, Harel, Stéphanie, Cordoliani, Florence, Fuzibet, Jean Gabriel, Oksenhendler, Eric, Clauvel, Jean-Pierre, Brouet, Jean-Claude, and Fermand, Jean-Paul
- Subjects
- *
CARCINOGENESIS , *XANTHOMA , *MONOCLONAL gammopathies , *MYELOMA proteins , *SERUM , *CRYOGLOBULINEMIA , *LIPOPROTEINS , *THERAPEUTICS - Abstract
Xanthomas are a common manifestation of lipid metabolism disorders. They include hyperlipemic xanthoma, normolipemic xanthoma, and a related condition, necrobiotic xanthogranuloma (NXG). All 3 forms can be associated with monoclonal immunoglobulin (MIg). In an attempt to improve diagnosis, understanding, and treatment of this association, we retrospectively analyzed a personal series of 24 patients (2 hyperlipemic xanthoma, 11 normolipemic xanthoma, and 11 NXG) and 230 well-documented reports from the literature. With the exception of the nodules and plaques featured in NXG, the clinical presentation of xanthomatous lesions usually resembled that seen in common hyperlipidemic forms and could not be used to suspect MIg-associated xanthomas. Extracutaneous sites were not rare. The MIg was an IgG in 80% of cases. Myeloma was diagnosed in 35%. Hypocomplementemia with low C4 fraction was present in 80% of studied patients. Low C1 inhibitor serum levels were found in 53%. Cryoglobulinemia was detected in 27%. These abnormalities suggest immune complex formation because of interactions between the MIg and lipoproteins and argue in favor of a causal link between MIg and xanthomas. Monoclonal gammopathy therapy could thus be an option. Indeed, among the patients who received chemotherapy, hematologic remission was accompanied by improvement in xanthoma lesions in several cases. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.